Cargando…

Change in timed walk as primary outcome measure of treatment response in HAMLET-P: HAM/TSP MuLticentre Efficacy trial-Prednisolone

Detalles Bibliográficos
Autores principales:	Martin, Fabiola, Inoue, Eisuke, Grassi, Maria Fernanda Rios, de Almeida Kruschewsky, Ramon, Cortese, Irene, Silva, Marcus T, Jacobson, Steve, Galvão-Castro, Bernardo, Yamano, Yoshihisa, Taylor, Graham, Bland, John Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045812/ http://dx.doi.org/10.1186/1742-4690-11-S1-P30

Ejemplares similares

HTLV-1 proviral load of HAM/TSP patients according to new diagnostic criteria of HAM/TSP
por: Grassi, Maria F R, et al.
Publicado: (2011)

HTLV-1 proviral load as an indicative marker of HAM/TSP: a systematic review of studies of patients with HAM/TSP
por: Bassi, Shiva Shaan, et al.
Publicado: (2014)

HAM/TSP introduction: systematic review of HAM/TSP clinical trials
por: Anderson, Rebecca, et al.
Publicado: (2014)

Evaluation of clinical outcome measures for HAM/TSP
por: Kikuchi, Takayuki, et al.
Publicado: (2015)

Timed walk as primary outcome measure of treatment response in clinical trials for HTLV-1-associated myelopathy: a feasibility study
por: Martin, Fabiola, et al.
Publicado: (2015)

Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019
por: Araujo, Abelardo, et al.
Publicado: (2021)

Clinical subtype of HAM/TSP based on clinical course and laboratory findings
por: Yamano, Yoshihisa, et al.
Publicado: (2011)

Monocyte accumulation is an early event in HAM/TSP pathogenesis, while monocyte activation and IFN-regulated gene expression persist in chronic HAM/TSP
por: Menezes, Soraya Maria, et al.
Publicado: (2015)

Anti-CD3 monoclonal antibody as a possible therapeutic alternative in HAM/TSP
por: Van Weyenbergh, Johan, et al.
Publicado: (2014)

Is age an effect modifier in the relationship between HAM / TSP and depression?
por: Boa-Sorte, Ney, et al.
Publicado: (2014)

Incidence of tropical spastic parapesis/ HTLV-1 associated myelopathy/ (TSP/HAM) in patients followed in a Reference center in Salvador, Brasil
por: Teixeira, Izabel Bou, et al.
Publicado: (2015)

Wish list: which biomarker studies in HAM/TSP should be funded by the God of all trial funds?
por: Yamano, Yoshihisa
Publicado: (2014)

HAM/TSP in relatives of HAM/TSP cases and in relatives of asymptomatic HTLV-1 carriers
por: Alvarez, Carolina, et al.
Publicado: (2014)

HAM/TSP and major depression: the role of age
por: Boa-Sorte, Ney, et al.
Publicado: (2015)

Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
por: Enose‐Akahata, Yoshimi, et al.
Publicado: (2021)

A selective defect in Fas-mediated apoptosis in HAM/TSP: An ex vivo, in vitro and in silico study
por: Menezes, Soraya Maria, et al.
Publicado: (2014)

Molecular and clinical analyses of HTLV-1 subgroups associated with the risk of developing HAM/TSP.
por: Saito, Mineki, et al.
Publicado: (2015)

Managing HAM/TSP with Fampridine
por: Menna-Barreto, M Marcio
Publicado: (2014)

Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan
por: Tsutsumi, Shuntaro, et al.
Publicado: (2019)

Biomarker to predict treatment response in patients with HTLV-1 associated myelopathy/Tropical spastic paraparesis (HAM/TSP)
por: Tamaki, Keiko, et al.
Publicado: (2015)

Role of HTLV-1 Tax and HBZ in the Pathogenesis of HAM/TSP
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2017)

B cell costimulatory molecules as potential biomarkers in HAM/TSP
por: Menezes, Soraya M, et al.
Publicado: (2011)

Clinical features of familial HAM/TSP
por: Nozuma, Satoshi, et al.
Publicado: (2014)

The plasticity of HTLV-1 infected CD4+CD25+CCR4+ T-cells through HTLV-1 tax in HAM/TSP
por: Araya, Natsumi, et al.
Publicado: (2011)

Characteristics of HAM/TSP after kidney transplantation from HTLV-1 positive living donors
por: Kimura, Miyuna, et al.
Publicado: (2015)

Immunophenotypic analysis of cerebrospinal fluid reveals concurrent development of ATL in the CNS of a HAM/TSP patient
por: Takeda, Reina, et al.
Publicado: (2020)

Recent epidemiologic trends of HAM/TSP in Japan
por: Matsuzaki, Toshio, et al.
Publicado: (2011)

Virus-induced CXCL10-CXCR3 positive feedback loop via astrocytes is critical for maintaining chronic inflammatory lesions in HAM/TSP
por: Sato, Tomoo, et al.
Publicado: (2014)

Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P)
por: Yamauchi, Junji, et al.
Publicado: (2022)

Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2019)

Characterization of glycans of CD4+T cells in HAM/TSP
por: Kodama, Daisuke, et al.
Publicado: (2014)

Contribution of galvanic vestibular stimulation for the diagnosis of HAM/TSP
por: Cunha, Luciana, et al.
Publicado: (2014)

Clinical trial of a humanized anti‐IL‐2/IL‐15 receptor β chain in HAM/TSP
por: Enose‐Akahata, Yoshimi, et al.
Publicado: (2019)

Functional capacity of natural killer cells in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients
por: Queiroz, Gabriel Andrade Nonato, et al.
Publicado: (2019)

Detrusor Arreflexia as an End Stage of Neurogenic Bladder in HAM/TSP?
por: Tannus, Matheus, et al.
Publicado: (2011)

Through the looking glass: CNS imaging findings in HAM/TSP
por: Massoud, Raya
Publicado: (2014)

Association Between HTLV-1 Genotypes and Risk of HAM/TSP
por: Saito, Mineki
Publicado: (2019)

What is the role of the thioredoxin antioxidant complex in relation to HAM/TSP?
por: Youssefi, Masoud, et al.
Publicado: (2020)

Identification of miRnas with possible prognostic roles for HAM/TSP
por: de Souza, Daniela Raguer Valadão, et al.
Publicado: (2023)

Gene expression and glycan profiling of CD4+T cells in HAM/TSP
por: Kodama, Daisuke, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_le2j9sq50slofulc4c79q342b2